Education
About Us
Working with TipRanks
Follow Us
Seres Therapeutics (MCRB)
NASDAQ:MCRB
MCRB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.54 - $1.53
Previous CloseN/A
Volume457.00K
Average Volume (3M)813.82K
Market Cap
$124.02M
Enterprise Value$204.62M
Total Cash (Recent Filing)$85.82M
Total Debt (Recent Filing)$7.25M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 07, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding174,358,750
10 Day Avg. Volume878,119
30 Day Avg. Volume813,824
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1937.83
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$5.50Price Target Upside674.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Seres Therapeutics News
PremiumCompany Announcements
Seres Therapeutics Advances SER-155 Program with FDA Support
PremiumCompany Announcements
Seres Therapeutics Earnings Call: Progress Amid Uncertainty---
Bulls Say, Bears Say
Bulls Say
FDA SupportThe FDA is supportive of a 30-day endpoint for BloodStream Infections, which is a positive development for the next SER-155 study.
Financial PerformanceSeres has received a $50M installment fee and is set to receive another $23.5M, extending its cash runway into 1Q26.
Partnership OpportunitiesThe progress of the SER-155 study should boost partnership opportunities, with expectations of an upfront payment supporting further research.
Bears Say
Financial StructureSeres currently has $66.8M cash and equivalents, funding their cash runway into 4Q25.
Strategic DecisionsMCRB announced the planned sale of the remainder of Vowst rights to partner Nestle, with payments totaling $75MM expected and potential future sales milestone payments up to $275MM.
---
Ownership Overview
0.45% Insiders
11.15% Mutual Funds
13.81% Other Institutional Investors
70.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MCRB FAQ
What was Seres Therapeutics’s price range in the past 12 months?
Seres Therapeutics lowest stock price was $0.54 and its highest was $1.53 in the past 12 months.
What is Seres Therapeutics’s market cap?
Seres Therapeutics’s market cap is $124.02M.
When is Seres Therapeutics’s upcoming earnings report date?
Seres Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Seres Therapeutics’s earnings last quarter?
Seres Therapeutics released its earnings results on Mar 13, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.197 by $0.107.
Is Seres Therapeutics overvalued?
According to Wall Street analysts Seres Therapeutics’s price is currently Undervalued.
Does Seres Therapeutics pay dividends?
Seres Therapeutics does not currently pay dividends.
What is Seres Therapeutics’s EPS estimate?
Seres Therapeutics’s EPS estimate is 0.03.
How many shares outstanding does Seres Therapeutics have?
Seres Therapeutics has 174,358,750 shares outstanding.
What happened to Seres Therapeutics’s price movement after its last earnings report?
Seres Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.197. Following the earnings report the stock price went down -7.246%.
Which hedge fund is a major shareholder of Seres Therapeutics?
Currently, no hedge funds are holding shares in MCRB
---
Seres Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (674.65% Upside)
$5.50 (674.65% Upside)
Blogger Sentiment
Bullish
MCRB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 49.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.56%
12-Months-Change
Fundamentals
Return on Equity
-3758.21%
Trailing 12-Months
Asset Growth
-61.01%
Trailing 12-Months
Company Description
Seres Therapeutics
Seres Therapeutics, Inc. (MCRB) is a biotechnology company focused on developing microbiome therapeutics. The company operates in the healthcare sector and is dedicated to creating innovative treatments for diseases by harnessing the therapeutic potential of the human microbiome. Seres Therapeutics' core products include a pipeline of biologically-derived drugs aimed at treating diseases such as Clostridium difficile infection (CDI) and other conditions linked to dysbiosis of the gut microbiota.
---
MCRB Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects significant progress with SER-155 and financial improvements, balanced by uncertainties in clinical development timelines and leadership transitions.Read More>---
MCRB Stock 12 Month Forecast
Average Price Target
$5.50
▲(674.65% Upside)
Technical Analysis
Amicus
―
Blueprint Medicines
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering MCRB
1 Year
1 Year Success Rate
13/21 ratings generated profit
1 Year Average Return
+118.98%
reiterated a sell rating 7 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 61.90% of your transactions generating a profit, with an average return of +118.98% per trade.
---